The efficacy and safety of once-daily beclomethasone dipropionate (BDP; 200 μg), in combination with the propellant hydrofluoroalkane-134a (HFA) was compared with that of budesonide turbuhaler (BUD-TH) 400 μg twice daily and fluticasone propionate inhaler (FP-IH) 250 μg twice daily in 40 patients with bronchial asthma or chronic obstructive pulmonary disease. All patients had used inhaled corticosteroids for at least 1 month. On randomization, 20 patients were switched to HFA-BDP and 20 patients remained on their existing BUD-TH or FP-IH treatment. After 8 weeks, HFA–BDP demonstrated a greater improvement in spirometric values, respiratory symptoms and β2-agonist use. No significant local adverse effects were observed. Blood cortisol levels remained in the normal range in both groups. We conclude that HFA–BDP (200 μg once-daily) offered more benefit in terms of clinical and spirometry indices than BUD-TH (400 μg twice daily) or FP-IH (250 μg twice daily) in patients with moderate asthma and chronic obstructive pulmonary disease.
Montreal Protocol: The Montreal Protocol on substances that deplete the ozone layer. Final Act (Nairobi: UNEP, 1987). Feb Reg1994; 59: 56276–56298.
2.
LeachC: Enhanced drug delivery through reformulating MDIs with HFA propellants: Drug deposition and its effect on preclinical and clinical programs. In: Respiratory Drug Delivery V. (DalbyRNByronPRFarrSJ, eds). Buffalo Grove (IL): Interpharm Press1996; 133–144.
3.
NagelMWWiersemaKJBatesSL: Size analysis of a pressurized metered dose inhaler-delivered solution formulation by an Aerosizer-LD time-of-flight aerosol particle size spectrometer. JAerosol Med2002; 15: 75–85.
4.
KaminWEGenzTRoederS: Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med2002; 15: 65–73.
5.
LeachCLDavidsonPJBoudreauRJ: Improved airway targeting with the CFC-free HFA–beclomethasone metered-dose inhaler compared with CHC–beclomethasone. Eur Respir J1998; 12: 1346–1353.
6.
LeachCLDavidsonPJHasselquistBE: Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: A crossover study in healthy volunteers. Chest2002; 122: 510–516.
7.
MatthysHNowakDHaderS: Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 micrograms day−1 delivered as an extrafine aerosol in adults with moderate asthma. Respir Med1998; 92 (Suppl A): 17–22.
8.
HampelFLisergEGuerinJC: Effectiveness of low doses (50 and 100 microg/bid) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group. J Asthma2000; 37: 389–398.
9.
DahlRRingdalNWardSM: Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC–beclomethasone dipropionate. Br J Clin Pract1997; 51: 11–15.
10.
BusseWWBrazinskySJakobsonK: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol1999; 104: 1215–1222.
11.
GrossGThompsonPChervinskyP: Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mcg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mcg, for the treatment of moderate asthma. Chest1999; 115: 343–351.
12.
MagnussenHon behalf of the Comparative Inhaled Steroid Investigation Group (CISIG): Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Respir Med2000; 94: 549–555.
13.
WorthHMuirJFPietersWR: Comparison of Hydrofluoroalkane–Beclomethasone Dipropionate Autohaler™ with Budesonide Turbuhaler™ in asthma control. Respiration2001; 68: 517–526.
14.
ReichelWDahlRRingdalN: Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract2001; 55: 100–106.
15.
FairfaxAJ: The relative clinical effectiveness of HFA–BDP and fluticasone propionate in asthma. Respir Med2000; 94 (Suppl D): S31–S36.
16.
AubierMWettengerRGansSJM: Efficacy of HFA–beclomethasone dipropionate extra-fine aerosol (800 μg day−1) versus HFA–fluticasone propionate (1000 μg day−1) in patients with asthma. Respir Med2001; 95: 212–220.
17.
DeromEPauwelsR: Pharmacokinetic and pharmacodynamic properties of inhaled beclomethasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin Pharmacokinet2005; 44: 815–836.
18.
SelfTHSameriRM: Efficacy of inhaled corticosteroids administered once daily for asthma. Am J Manag Care2003; 9: 91–99.
19.
CalverleyP: Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Pro/Con Editorials. Am J Respir Crit Care Med2000; 161: 341–344.
20.
BarnesP: Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Pro/Con Editorials. Am J Respir Crit Care Med2000; 161: 342–344.
21.
Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (online). November 2006. Available from URL: http://www.goldcopd.com (last accessed 14 March 2007).
22.
van BeurdenWJCHarffGADekhuijkenPNR: Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration2003: 70: 242–248.
23.
JohnMBosseSOltmannsU: Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease. Respir Med2005; 99: 1418–1424.
24.
National Heart, Lung and Blood Institute, Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention (online). November 2006. Available from URL: http://www.ginasthma.com (last accessed 14 March 2007).
25.
SinDDLacyPYorkE: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2004; 170: 760–765.
26.
HuiartLErnstPRanouilX: Low dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J2005; 25: 634–639.
Van den BurgtJABusseWWMartinRJ: Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol2000; 106: 1209–1226.
29.
HarrisonLIColiceGLDonnellD: Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: A 14-day dose–response study. J Pharm Pharmacol1999; 51: 263–269.
30.
DekhuijkenPNRHonourJW: Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: Do we understand their interaction?Respir Med2000; 94: 1–5.
